TECP
RCUS icon

Trails Edge Capital Partners’s Arcus Biosciences RCUS Stock Holding History

Trails Edge Capital Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,047,935
Closed -$22.6M – 39
2026
Q1 		$22.6M Buy
1,047,935
+131,622
+14% +$2.84M 5.19% 8
2025
Q4 		$21.8M Buy
+916,313
New +$18.7M 5.4% 8

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Trails Edge Capital Partners's RCUS Position: Q2 2026 in Review

Trails Edge Capital Partners sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 1,047,935 shares — an estimated $22.6M sold.

Trails Edge Capital Partners first reported a position in RCUS in Q4 2025 and held it in 2 quarters. The position peaked at $22.6M in Q1 2026. 230 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Trails Edge Capital Partners reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
  • Trails Edge Capital Partners sold 1,047,935 Arcus Biosciences shares in Q2 2026, an estimated $22.6M.
  • Trails Edge Capital Partners first reported a position in Arcus Biosciences in Q4 2025 and held it in 2 quarters.
  • Trails Edge Capital Partners's Arcus Biosciences position peaked at $22.6M in Q1 2026.
  • 230 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.